400-920-2911 sales@csnpharm.cn
CAS No.: 1005342-46-0
Synonyms: NVP-LCL161
LCL161 is an IAP inhibitor, inhibits XIAP activity in HEK293 cell with IC50 of 35 nM, also inhibits cIAP1 activity in MDA-MB-231 cell with IC50 of 0.4 nM.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02098161 | Leukemia | Phase 2 | Recruiting | December 2020 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse << |
NCT03111992 | Multiple Myeloma | Phase 1 | Recruiting | May 27, 2020 | United States, Arizona ... more >> Novartis Investigative Site Recruiting Phoenix, Arizona, United States, 85054 United States, Tennessee Novartis Investigative Site Recruiting Nashville, Tennessee, United States, 37203 Contact: Kimberly Cox 615-329-7413 Kimberly.Cox3@scresearch.net Principal Investigator: Jesus G. Berdeja Canada, Quebec Novartis Investigative Site Recruiting Montreal, Quebec, Canada, H3T 1E2 Germany Novartis Investigative Site Recruiting Heidelberg, Germany, 69120 Novartis Investigative Site Recruiting Kiel, Germany, 24105 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20133 Spain Novartis Investigative Site Recruiting Salamanca, Castilla Y Leon, Spain, 37007 Novartis Investigative Site Recruiting Madrid, Spain, 28006 Switzerland Novartis Investigative Site Recruiting Locarno, Switzerland, 6600 Collapse << |
NCT02890069 | Colorectal Cancer, Non-small C... more >>ell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Collapse << | Phase 1 | Recruiting | December 19, 2019 | - |
实验方案
技术信息
CAS号 | 1005342-46-0 | 储存条件 |
|
|||||||
分子式 | C26H33FN4O3S | 运输 | 蓝冰 | |||||||
分子量 | 500.63 | 别名 | NVP-LCL161 | |||||||
溶解度 |
|
动物实验配方 |
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
human AGS cells | 2.5 μM | Apoptosis assay | 5 days | Induction of sensitization of human AGS cells to conatumumab-induced apoptosis assessed as cell viability at 2.5 uM after 5 days by MTS assay | 24093940 |
human BxPC3 cells | 3.3 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced cytotoxicity against human BxPC3 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
human Capan1 cells | 2.5 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced apoptosis in human Capan1 cells at 2.5 uM after 5 days by MTS assay | 24093940 |
human Capan1 cells | 2.5 μM | Apoptosis assay | 5 days | Potentiation of conatumumab-induced apoptosis in human Capan1 cells at 2.5 uM after 5 days by MTS assay | 24093940 |
human H460 cells | 3.3 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced cytotoxicity against human H460 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
human HCT15 cells | 3.3 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced cytotoxicity against human HCT15 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
human LOX cells | 3.3 μM | Cytotoxic assay | 3 days | Potentiation of conatumumab-induced cytotoxicity against human LOX cells at 3.3 uM after 3 days by MTS assay | 24083782 |
human LS180 cells | 3.3 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced cytotoxicity against human LS180 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
human MDA-MB-231 cells | 0.37-3.3 μM | Function assay | 19 h | Inhibition of cIAP1/2 in human MDA-MB-231 cells assessed as induction of TNFalpha level at 0.37 to 3.3 uM after 19 hrs by ELISA | 24093940 |
human PC3 cells | 2.5 μM | Apoptosis assay | 5 days | Induction of sensitization of human PC3 cells to conatumumab-induced apoptosis assessed as cell viability at 2.5 uM after 5 days by MTS assay | 24093940 |
human SKMES1 cells | 2.5 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced apoptosis in human SKMES1 cells at 2.5 uM after 5 days by MTS assay | 24093940 |
human SKMES1 cells | 2.5 μM | Apoptosis assay | 5 days | Potentiation of conatumumab-induced apoptosis in human SKMES1 cells at 2.5 uM after 5 days by MTS assay | 24093940 |
human SW620 cells | 3.3 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced cytotoxicity against human SW620 cells at 3.3 uM after 5 days by MTS assay | 24083782 |
human SW620 cells | 1.1 μM | Cytotoxic assay | 5 days | Potentiation of conatumumab-induced cytotoxicity against human SW620 cells at 1.1 uM after 5 days by MTS assay | 24083782 |
human U118MG cells | 2.5 μM | Apoptosis assay | 5 days | Potentiation of conatumumab-induced apoptosis in human U118MG cells at 2.5 uM after 5 days by MTS assay | 24093940 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02098161 | Leukemia | Phase 2 | Recruiting | December 2020 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse << |
NCT03111992 | Multiple Myeloma | Phase 1 | Recruiting | May 27, 2020 | United States, Arizona ... more >> Novartis Investigative Site Recruiting Phoenix, Arizona, United States, 85054 United States, Tennessee Novartis Investigative Site Recruiting Nashville, Tennessee, United States, 37203 Contact: Kimberly Cox 615-329-7413 Kimberly.Cox3@scresearch.net Principal Investigator: Jesus G. Berdeja Canada, Quebec Novartis Investigative Site Recruiting Montreal, Quebec, Canada, H3T 1E2 Germany Novartis Investigative Site Recruiting Heidelberg, Germany, 69120 Novartis Investigative Site Recruiting Kiel, Germany, 24105 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20133 Spain Novartis Investigative Site Recruiting Salamanca, Castilla Y Leon, Spain, 37007 Novartis Investigative Site Recruiting Madrid, Spain, 28006 Switzerland Novartis Investigative Site Recruiting Locarno, Switzerland, 6600 Collapse << |
NCT02890069 | Colorectal Cancer, Non-small C... more >>ell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Collapse << | Phase 1 | Recruiting | December 19, 2019 | - |
NCT01617668 | Breast Cancer | Phase 2 | Completed | - | - |
NCT01098838 | Advanced Solid Tumors | Phase 1 | Completed | - | United States, North Carolina ... more >> UNC/ Lineberger Comprehensive Cancer Center Dept. of LinbergerCancerCtr(2) Chapel Hill, North Carolina, United States, 27599-7295 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 United States, Tennessee Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2) Nashville, Tennessee, United States, 37203 Collapse << |
NCT01617668 | - | - | Completed | - | - |
NCT02649673 | Small Cell Lung Cancer ... more >> Ovarian Cancer Collapse << | Phase 1 Phase 2 | Recruiting | July 27, 2019 | United States, Florida ... more >> Florida Cancer Specialists-Sarasota Recruiting Sarasota, Florida, United States, 34232 United States, Oklahoma Oklahoma University Health Science Center/Stephenson Cancer Center Recruiting Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Tennessee Oncology PLLC Recruiting Nashville, Tennessee, United States, 37203 Collapse << |
NCT01955434 | Recurrent Plasma Cell Myeloma ... more >> Refractory Plasma Cell Myeloma Collapse << | Phase 2 | Completed | - | United States, Arizona ... more >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse << |
NCT01968915 | Neoplasms | Phase 1 | Completed | - | Japan ... more >> Novartis Investigative Site Nagoya-city, Aichi, Japan, 466-8560 Novartis Investigative Site Kobe-city, Hyogo, Japan, 650-0017 Collapse << |
NCT01955434 | - | - | Completed | - | - |
NCT01934634 | Metastatic Pancreatic Cancer | Phase 1 | Unknown | - | United States, Texas ... more >> 2 Sites incl Tyler, TX and Dallas, TX, Texas, United States Collapse << |
NCT01240655 | Solid Tumors | Phase 1 | Completed | - | United States, Massachusetts ... more >> Dana Farber Cancer Institute SC Boston, Massachusetts, United States, 02215 United States, North Carolina University of North Carolina Lineberger Comp Cancer Ctr Chapel Hill, North Carolina, United States, 27514 United States, Tennessee Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2) Nashville, Tennessee, United States, 37203 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1L3 Italy Novartis Investigative Site Modena, MO, Italy, 41100 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Collapse << |
靶点 | Description | IC50 |
---|
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网